Dateline City:
KENILWORTH, N.J.
Application Based on Data from KEYNOTE-010, Which Showed Superior Overall Survival for Patients Taking KEYTRUDA Compared to Chemotherapy in Patients with PD-L1 Expression on One Percent or More of the Cancer Cells
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
accepted for review a new supplemental Biologics License Application
(sBLA) for KEYTRUDA (pembrolizumab), the companys anti-PD-1
therapy, to include data from KEYNOTE-010.
Language:
English
Contact:
MerckMedia:Pamela Eisele, (267) 305-3558orKim Hamilton, (908) 740-1863orInvestor:Teri Loxam, (908) 740-1986orJustin Holko, (908) 740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more